Background: Sphingolipids, like phytosphingosine (PS) are part of cellular membranes of yeasts, vegetables and fruits. Addition of PS to the diet decreases serum cholesterol and free fatty acid (FFA) levels in rodents and improves insulin sensitivity. Objective: To study the effect of dietary supplementation with PS on cholesterol and glucose metabolism in humans. Methods: Twelve men with the metabolic syndrome (MetS) (according to the International Diabetes Federation (IDF) criteria; age 51 ± 2 years (mean ± s.e.m.); body mass index (BMI) 32 ± 1 kg/m 2 ) were randomly assigned to 4 weeks of PS (500 mg twice daily) and 4 weeks of placebo (P) in a double-blind cross-over study, with a 4-week wash-out period between both interventions. At the end of each intervention anthropometric measures and serum lipids were measured and an intravenous glucose tolerance test (IVGTT) was performed. Results: Phytosphingosine did not affect body weight and fat mass compared with P. PS decreased serum total cholesterol (5.1 ± 0.3 (PS) vs 5.4 ± 0.3 (P) mmol/l; Po0.05) and low-density lipoprotein (LDL)-cholesterol levels (3.1 ± 0.3 (PS) vs 3.4 ± 0.3 (P) mmol/l; Po0.05), whereas it did not alter serum triglyceride and high-density lipoprotein (HDL)-cholesterol levels. In addition, PS lowered fasting plasma glucose levels (6.2 ± 0.3 (PS) vs 6.5 ± 0.3 (P) mmol/l; Po0.05). PS increased the glucose disappearance rate (K-value) by 9.9% during the IVGTT (0.91 ± 0.06 (PS) vs 0.82 ± 0.05 (P) %/min; Po0.05) at similar insulin levels, compared with P, thus implying enhanced insulin sensitivity. PS induced only minor gastrointestinal side effects. Conclusion: Dietary supplementation of PS decreases plasma cholesterol levels and enhances insulin sensitivity in men with the MetS.
Introduction
Sphingolipids are ubiquitous functional components in food and, therefore, constituents of our normal daily diet, although the amounts are relatively small (Vesper et al., 1999) . Sphingolipids belong to the class of amphiphilic membrane lipids. They consist of a long-chain sphingoid base, a polar head group and a fatty acid, which is linked by an amide bond (Merrill et al., 1997) . Different head groups on the backbone separate the individual sphingolipids from one another. At least 300 different sphingolipids were identified in mammals. Sphingolipids primarily serve as critical components of cell membranes, although they are also present in small amounts in lipoproteins and other lipid-rich structures (Harder and Simons, 1997) . Certain complex sphingolipids are involved in specific functions, such as cell growth, division, differentiation, survival and death (Berra et al., 2002) . Sphingolipids in food cross the intestinal membrane, and are biologically active (Schmelz et al., 1994) . Nevertheless, it is uncertain if they have health benefits in humans. Phytosphingosine (PS), one of the sphingolipids, is a constituent of plants, fruits and yeasts (Vesper et al., 1999) . Normal daily intake of PS averages 50 mg in humans. In high fat-fed, insulin-resistant ApoE3 Leiden mice, PS treatment (diet supplemented with 1% PS for 5 weeks) decreased plasma cholesterol and triacylglycerol levels by B57%. This was, at least, in part explained by the intestinal effects of PS, as it reduced intestinal absorption of dietary cholesterol and free fatty acids (FFAs) by B40% (Duivenvoorden et al., 2006) . PS treatment also seemed to positively affect insulin sensitivity in these animals (data not published). The lipoprotein profile of these mice closely resembles the pattern of dyslipidemia characteristic of the metabolic syndrome (MetS) in humans. At present, it is unclear whether addition of PS to the diet is also beneficial for humans.
The MetS consists of a constellation of metabolic abnormalities, including glucose intolerance, obesity, dyslipidemia and hypertension, all well-defined cardiovascular risk factors. At present, 25% of adult Americans meet the criteria of the MetS (Ford et al., 2002) . Having the MetS more than doubles the risk of developing cardiovascular disease (CVD) and type II diabetes (Isomaa et al., 2001; Ford, 2005) . As for now, the only intervention targeting all aspects of the MetS is lifestyle change, consisting of diet-induced weight loss and increasing physical activity. However, the chances of long-term adherence (a prerequisite for success) of such an intervention are low. The use of drugs that improve individual components of the MetS is likely to cause polypharmacy in patients, which diminishes patient compliance and leads to side effects. Thus, therapeutic tools targeting multiple components of the syndrome simultaneously are needed. This study was meant to elucidate the effects of dietary supplementation with PS on blood cholesterol levels and insulin sensitivity in male subjects with the MetS.
Patients and methods

Patients
Twelve men with the MetS according to the criteria of the International Diabetes Federation (Alberti et al., 2006) were recruited through advertisements in local newspapers. Additional inclusion criteria were age, between 18 and 65 years; body mass index, between 27 and 40 kg/m 2 ; and homeostatic model assesment-Insulin resistance (HOMA-IR)42.0. Subjects were excluded from the study if they had a history of any chronic disease (including cardiovascular disease and type II diabetes mellitus) or if they were smokers. No subject used medication that could affect the investigated metabolic markers. All subjects had a stable body weight for 3 months before participation, and were instructed not to alter lifestyle (eating, drinking and exercise) until the end of the study. Before participation the subjects gave written informed consent after oral and written explanation of the study had been provided. The study was approved by the Medical Ethical Committee of Leiden University Medical Center.
Study design
Subjects enrolled in a randomized double-blind placebo (P)-controlled cross-over intervention study with a 4 week washout period in between the two interventions. Subjects were randomly assigned to P or PS as first intervention. They received PS (Cosmoferm, Delft, the Netherlands; encapsulated by Utrecht Medical Centre, Utrecht, the Netherlands) in a dosage of 500 mg twice daily and P capsules also twice daily for 4 weeks. At the end of each intervention patients were admitted to the research center to carry out an intravenous glucose tolerance test (Lundback, 1962) . During both intervention periods patients visited the research center weekly for anthropometric measurements, registration of adverse events (both subjective side effects and laboratory abnormalities were recorded) and compliance registration (weekly pill count).
Study days
At the end of each intervention patients were admitted to the clinical research center after an overnight fast for an intravenous glucose tolerance test. First, anthropometric measurements (weight, length and waist and hip circumference) were obtained together with measurements of blood pressure and body fat mass by bioelectrical impedance analysis (Bodystat, Bodystat Ltd., Douglas, Isle of Man, UK). Subsequently, an intravenous cannula was placed to draw a basal blood sample followed by an intravenous glucose tolerance test. In all, 25 gm of glucose was infused in 4 min by a volumetric pump (Pilot C syringe pump, Fresenius Vial, Brezins, France), with blood sampling at 0, 2, 4, 6, 8, 10, 12, 20, 30, 40, 50, 60, 90 and 120 min from a second cannula in a contralateral arm vein. Glucose, insulin, C-peptide and FFAs levels were determined in these samples.
Assays
Serum glucose, cholesterol, high-density lipoprotein cholesterol and triglycerides were measured with a fully automated P-800 module (Roche, Almere, the Netherlands). Low-density lipoprotein (LDL) cholesterol was calculated with the Friedewald equation. Insulin and C-peptide were detected with an immunometrische assay on an automated Immulite 2500 (Siemens, Breda, the Netherlands).
Statistical analysis and mathematical calculations
The glucose disappearance rate (K-value) was determined by log-linear regression of the glucose concentrations against time over the period from 10 to 120 min post-glucose loading. Total and incremental areas under the curve of glucose, insulin, C-peptide and FFA were determined over Phytosphingosine improves the metabolic syndrome M Snel et al the periods from 0 to 120 min (glucose) and 10 to 120 min (insulin, C-peptide and FFA) post-glucose loading. Baseline levels were defined as plasma glucose, insulin, C-peptide and FFA levels at time 0 min (Lundback, 1962) . Data are presented as mean±s.e.m. For comparisons between P and PS treatment a Student's t-test for paired samples was used. When appropriate, non-parametric (Wilcoxon's signed-rank test) tests for paired samples were carried out. All analyses were done using SPSS for Windows version 16.0 (SPSS, Chicago, IL, USA). A P-value of o0.05 was considered statistically significant.
Results
Patient characteristics
Anthropometric parameters are presented in Table 1 . There were no differences in anthropometric parameters, fat mass and blood pressure after 4 weeks of treatment with P vs PS. The patients' compliance was very good; 2 respectively 3 patients missed only one capsule of 500 mg during the P respectively PS-treatment period.
Fasting cholesterol levels A total of 4 weeks of PS treatment decreased total cholesterol levels (5.1 ± 0.3 (PS) vs 5.4 ± 0.3 (P) mmol/l; Po0.05) and LDL-cholesterol levels (3.1 ± 0.3 (PS) vs 3.4 ± 0.3 (P) mmol/l; Po0.05) as compared with 4 weeks of treatment with P, whereas PS did not alter triglyceride and HDL-cholesterol levels ( Figure 1 and Table 2 ).
Metabolic parameters
Phytosphingosine decreased fasting serum glucose levels compared with P (6.2±0.3 (PS) vs 6.5±0.3 (P) mmol/l; Po0.05). However, PS did not alter fasting levels of insulin, C-peptide and FFAs (Table 2) .
Phytosphingosine did not affect the total and the incremental areas under the curve of glucose, insulin, C-peptide and FFA levels during intravenous glucose tolerance test (Table 3) . However, PS improved the K-value (a parameter of the glucose disappearance rate; 0.91±0.06 (PS) vs 0.82±0.05 (P) %/min; Po0.05) at equal insulin levels, implying enhanced insulin sensitivity (Figure 2 ). Phytosphingosine improves the metabolic syndrome M Snel et al
Safety and side effects
Administration of PS 500 mg twice daily for 4 weeks was well tolerated. Liver enzymes, creatinin levels and hemoglobin levels were not affected by PS treatment (data not shown). Subjects only reported minor side effects, which were all gastrointestinal complaints (PS vs P: diarrhea, 4 vs 3; pyrosis, 3 vs 1; nausea, 3 vs 2; and abdominal discomfort, 4 vs 1 subjects).
Discussion
This study indicates that dietary supplementation with 500 mg PS twice daily significantly lowers total and LDLcholesterol by 6 and 10%, respectively, and enhances insulin sensitivity in men with the MetS. Side effects were minimal and of gastrointestinal nature. This study confirms in humans the metabolic effects of dietary PS, previously documented in rodents (Duivenvoorden et al., 2006) . Blood cholesterol concentrations can be modulated by changes in the intake of dietary fat and cholesterol.
However, implementation of dietary advices reduces total cholesterol levels only by 3-6% (Tang et al., 1998) . In addition, reductions in LDL-cholesterol and total cholesterol levels can be accomplished by dietary supplementation of plant sterol esters. Plant sterol esters possess the same cholesterol-lowering capacity as PS in this dosage. In the studies carried out, total cholesterol levels decreased by 4-10% and LDL-cholesterol levels by 6-10% after treatment with 1-3.25 g plant sterol esters for 3.5-52 weeks (Miettinen et al., 1995; Hendriks et al., 1999 Hendriks et al., , 2003 . The maximum cholesterol-lowering effect with plant sterol esters treatment is reached with a dosage of B2.5 g. Therefore, the cholesterol-lowering capacity of 1 g PS for 4 weeks is greater than that of implementations of dietary advices and equal to that of dietary supplementation with B2.5 g plant sterol esters. However, we expect a larger cholesterol-lowering effect with a higher dosage of dietary PS supplementation.
Several mechanisms could account for the less explicit reduction in cholesterol levels in our study as compared with the previous rodent studies. First, the effects of PS on cholesterol metabolism are dose-dependent and the rodent studies were carried out with higher amounts of PS in the diet (1% of the diet) than used in this study (0.2% of the diet) (Imaizumi et al., 1992; Duivenvoorden et al., 2006) . Second, the study may have been too short to show the full decrease in cholesterol levels. The duration of treatment with PS was based on the rodent study, which treated mice with PS for 5 weeks (Duivenvoorden et al., 2006) . Studies with plant sterol esters-enriched spread observed a maximal cholesterollowering effect after 3 months (Miettinen et al., 1995) . Further studies should elucidate whether longer treatment with PS could extend the magnitude of the cholesterol-lowering effect. The exact mechanism by which PS lowers blood cholesterol levels is not fully understood, but includes decreased absorption of dietary cholesterol from the gut (Noh and Koo, 2004; Duivenvoorden et al., 2006) .
The observed decrease in fasting plasma glucose levels can be because of decreased intestinal glucose uptake and/or decreased basal endogenous glucose production by Phytosphingosine improves the metabolic syndrome M Snel et al the liver. In one study sphingomyelin, another sphingolipid, decreases the absorption of glucose in the intestine in mice (Barrenetxe et al., 2006) . No data are available on the glucose absorption from the intestine after PS treatment. In rodents dietary PS leads to an improvement in hepatic steatosis, this is often accompanied by an improvement in hepatic insulin resistance and thus a decreased basal endogenous glucose production (Petersen et al., 2005; Ravikumar et al., 2008) . The K-value is a measure for the glucose disappearance rate after a glucose load. K-values in patients with type II diabetes mellitus treated with oral blood glucose-lowering agents and/or insulin vary between 0.4-0.7 (%/min). Subjects without insulin resistance have a K-value above 1 (%/min) (Lundback, 1962) . The increase in K-value was found in the absence of an increase in either fasting or glucose-stimulated serum insulin levels. This indicates improved tissue insulin sensitivity and increased peripheral glucose uptake. The underlying mechanism of the improvement in insulin sensitivity is unclear. Possibly PS acts like acarbose. Acarbose diminishes the postprandial glucose uptake, thereby decreasing glucotoxicity and it's associated inflammation and insulin resistance of muscle and liver (Lieber et al., 2004; Segal et al., 2005; Okada et al., 2009) . It is very likely that PS diminishes postprandial glucose uptake as well.
A strength of our study was the placebo-controlled crossover design, which is an effective method for balancing confounding factors between treatment periods. A possible weakness was the small sample size. As this was the first study with PS in humans, we could not carry out a formal power calculation. However, the results were highly significant. Nevertheless, the results of our study should be confirmed in a study with a bigger sample size.
In conclusion, a relatively low-dose of PS decreases serum total and LDL-cholesterol levels and fasting plasma glucose and improves glucose disappearance in men with the MetS within 4 weeks. Therefore, sphingolipids like PS may provide an additional dietary tool to treat the metabolic features of the MetS.
